Loading stock data…
Vera Therapeutics (VERA)
$35.45-0.90 (-2.48%)
Market ClosedLast close Jul 24
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vera Therapeutics, Inc. in the Healthcare sector is trading at $35.45 with a market capitalization of $2.4B. Wall Street consensus targets $81.79 (14 analysts), implying a +130.7% move over the next 12 months. The stock is currently 37% below its 52-week high of $56.05, remaining 8.8% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +130.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$125.13M↓ | -$94.21M↓ | -$83.93M↓ | -$80.14M↓ | -$57.19M |
| Net Income | -$121.03M↓ | -$91.10M↓ | -$80.29M↓ | -$76.53M↓ | -$51.69M |
Peer Comparison
JNJUNHPFE
Fundamentals
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion pr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.38B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-73.84%
Volume
Today's trading volume
786,074
Recent News
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
Vera Therapeutics (NASDAQ:VERA) said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease progression. The company said TRUTAKNA is the first and only BAFF and APRIL inhibitor indicated to redu
Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)?
Vera Therapeutics recently received FDA accelerated approval for TRUTAKNA™ (atacicept-vymj), a first-in-class dual BAFF/APRIL inhibitor to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. This approval, based on interim Phase 3 data showing meaningful proteinuria reductions, marks Vera’s first commercial therapy and introduces a home-use weekly autoinjector option targeting the immunological drivers of IgA nephropathy. We’ll now examine how...
Vera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA Approval
Vera Therapeutics (VERA) has drawn fresh attention after the US Food and Drug Administration granted accelerated approval for TRUTAKNA to treat adults with IgA nephropathy who are at risk for disease progression. See our latest analysis for Vera Therapeutics. The FDA decision sits against a mixed share price backdrop for Vera Therapeutics, with a 30 day share price return of 33.45% but the year to date share price return still down 12.69%. At the same time, the 1 year total shareholder return...
Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% Run
Vera Therapeutics has delivered a strong 184.9% return over the past 5 years, yet its valuation checks and current market multiples point to a stock that may now be leaning expensive rather than clearly cheap. With accelerated FDA approval for Trutakna helping to reshape expectations, the question is how much of that optimism is already reflected in the price. The 184.9% 5 year return suggests long term holders have already seen substantial gains, which can limit upside if expectations are...
Sector Update: Healthcare Stocks Gain Late Afternoon
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S